Hetq 300 Tablet contains Hydroxychloroquine 300 mg, an antimalarial and immunomodulatory agent widely used in the treatment and prevention of malaria, as well as in autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus. Hydroxychloroquine acts by interfering with lysosomal activity and autophagy, modulating the immune response and reducing inflammation. This medication is indicated for the prophylaxis and treatment of acute attacks of malaria caused by Plasmodium species sensitive to Hydroxychloroquine. Additionally, it is prescribed to manage symptoms and disease progression in autoimmune disorders by decreasing joint inflammation, pain, and skin manifestations. Hetq 300 Tablet should be administered under medical supervision, with dosage tailored according to the specific condition and patient response. Common adverse effects include gastrointestinal disturbances, headache, dizziness, and, rarely, retinopathy with long-term use, necessitating regular ophthalmologic monitoring. Caution is advised in patients with pre-existing retinal or visual field changes, hepatic or renal impairment, and those on concomitant medications that may prolong the QT interval. Pregnant or breastfeeding women should consult their healthcare provider before use. Adherence to prescribed dosage and periodic clinical evaluation are essential to maximize therapeutic benefits and minimize potential risks associated with Hydroxychloroquine therapy.